About Uncommon
Uncommon is a Consumer company based in Cambridge (United Kingdom) founded in 2017 by Benjamina Bollag and Ruth Faram, and was acquired by Meatable in August 2025. High-quality pork products are produced from healthy pork cells. It operates on a HealthTech model. Uncommon has raised $30 million across 1 funding round from investors including Meatable, Balderton Capital and Redalpine. Its chief executive, as recorded, is Benjamina Bollag. Uncommon offers products and services including SymphoRNA. Its focus areas include Healthcare, Biotechnology and Nucleic Acid Technology. Its competitors include ENOUGH, VFC Foods and Ivy Farm; 3 of its 3 listed competitors have raised funding.
Company details
Uncommon is engaged in developing advanced nucleic acid delivery technology through its SymphoRNA platform. The company has transitioned from its previous cultivated platform, which was sold to Vow and Meatable, to focus on innovative solutions in the biotechnology sector. Its efforts are directed towards creating impactful health technology solutions.
- Headquarters Cambridge, United Kingdom
- Founders Benjamina Bollag, Ruth Faram
- Stage Acquired
- SectorsConsumer
- Email••••••••
- Website uncommonbio.co
- Social LinkedIn X YouTube
- Acquired by Meatable (Aug 2025)
Products & Services of Uncommon
Uncommon offers a comprehensive portfolio of products and services, including SymphoRNA.
A platform for nucleic acid delivery technology.
Apps and channels of Uncommon
its YouTube channel mega has 261 subscribers and 3 videos.
Videos from Uncommon
The most watched videos on Uncommon's YouTube channel, mega (261 subscribers). Click a video to play it here.
More on mega.
Funding Insights of Uncommon
Uncommon has successfully raised a total of $30M through 1 strategic funding round. The most recent funding activity was a Series A round of $30 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $30M
- Total Rounds 1
- Last Round Series A — $30M
- First Round $30M
(Jun 2023)
- Investors Count 6
All 1 funding rounds of Uncommon with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2023 | $30M | Series A | – | Balderton Capital, Lowercarbon Capital |
7 investors in total: 5 institutional and 2 angel.
Investors in Uncommon
Uncommon has secured backing from 7 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Meatable, Balderton Capital and Redalpine.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage investments are directed toward ICT and health tech startups. | redalpine.com | Zurich, Switzerland | ||
Multistage venture capital investments are focused on technology sectors. | 2000 | balderton.com | London, United Kingdom | |
Venture capital fund focused on tech startups | lowercarboncapital.com | New York, United States | ||
East Alpha offers quantitative research and technology for commodity markets globally. | eastalpha.co | United Kingdom | ||
MA Max Altman | Indian angel investor with focus on early-stage tech startups. | unknown_99e487dbdb4944c9a | ||
MZ Miray Zaki | Angel investor and advisor focused on early-stage Indian startups. | unknown_56d7fc864ab4402f8 | ||
Produces and supplies lab-cultured meat products | 2018 | meatable.com | Leiden, Netherlands |
Investor details for Uncommon
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Uncommon
2 people are tracked at Uncommon (2 in leadership).
| Name | Role | Group |
|---|---|---|
Benjamina Bollag | Co-Founder & CEO | Leadership |
Ruth Faram | Co-Founder | Leadership |
Complete people profiles for Uncommon
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Uncommon
3 dated milestones of Uncommon across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Uncommon is founded.
- Funding First funding round of $30.0M.
- Exit Acquired by Meatable.
Competitors of Uncommon
Uncommon has 3 listed competitors in our database, 3 of them funded. They include ENOUGH, VFC Foods and Ivy Farm.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| enough-food.com | 2015 | Glasgow, United Kingdom | $110.82M | 20 | Fungi-based meat substitutes are developed under the ENOUGH brand. | |
| vfcfoods.com | 2019 | York, United Kingdom | $21.21M | 18 | Provider of plant-based food products to replace meat | |
| ivy.farm | 2019 | Oxford, United Kingdom | $40.43M | Cultivated plant-based meat products are developed by Ivy Farm. |
Detailed competitors of Uncommon
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Uncommon
The website of Uncommon (uncommonbio.co) receives about 1.9K visits a month.
- Monthly visits1.9K
Websites whose visitors overlap most with Uncommon. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
bemoreuncommon.com | bemoreuncommon.com | 100% | #8,301,771 | – | |
uncommon.co.uk | uncommon.co.uk | 89% | #996,464 | – | |
uncommon.studio | uncommon.studio | 82% | #920,597 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Uncommon
Complete news archive for Uncommon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Uncommon
Uncommon was founded in 2017 and raised its 1st funding round 6 years after it was founded.
Uncommon is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Benjamina Bollag is the CEO of Uncommon, as recorded in our data. They have also founded this company.
Uncommon is a funded company, having raised a total of $30M across 1 funding round to date. The company's 1st funding round was a Series A of $30M, raised on Jun 2023.
Uncommon is engaged in developing advanced nucleic acid delivery technology through its SymphoRNA platform. The company has transitioned from its previous cultivated platform, which was sold to Vow and Meatable, to focus on innovative solutions in the biotechnology sector. Its efforts are directed towards creating impactful health technology solutions.
Uncommon offers SymphoRNA.
Uncommon has 7 investors. Key investors include Meatable, Balderton Capital, Redalpine, East Alpha, and Lowercarbon Capital.
Yes. Uncommon was acquired by Meatable in August 2025.